Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabil Adra

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Clinical Genitourinary Cancer|March 12, 2026
Quantitative Assessment of Seminoma in the Testicle Among Nonseminomatous Germ Cell Tumor Patients on Operative Difficulty, Morbidity and Pathological Outcomes at Postchemotherapy RPLNDSean Q Kern, Naveen Krishnan, Nabil Adra, et al.
Journal of Clinical Pathology|June 6, 2019
Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomyMartin J Magers, Hristos Z Kaimakliotis, Marcelo P Barboza, et al.
Clinical Genitourinary Cancer|December 26, 2022
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate CancerNeal Shore, Begoña Mellado, Satish Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2023
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell TumorsJennifer M King, Michael Cheng, Kenneth Kesler, et al.
Clinical Genitourinary Cancer|April 23, 2023
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-onlyNoah H Richardson, Sandra K Althouse, Ryan Ashkar, et al.
The Journal of Urology|February 1, 2020
Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant ChemotherapyAntoin Douglawi, Adam Calaway, Isamu Tachibana, et al.
Investigational New Drugs|June 27, 2022
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumorsNabil Adra, David J Vaughn, Lawrence H Einhorn, et al.
Urologic Oncology|April 17, 2022
Artificial intelligence in prostate cancer: Definitions, current research, and future directionsRose S George, Arkar Htoo, Michael Cheng, et al.
Cancer Medicine|February 6, 2025
Prediction Model for Brain Metastasis in Patients With Metastatic Germ-Cell TumorsTareq Salous, Ryan Ashkar, Sandra K Althouse, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2026
How to Optimize Treatment for Patients With Poor-Risk Testicular CancerNoah Richardson, Alok K Tewari, Patrizia Giannatempo, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Clinical Genitourinary Cancer|March 12, 2026
Quantitative Assessment of Seminoma in the Testicle Among Nonseminomatous Germ Cell Tumor Patients on Operative Difficulty, Morbidity and Pathological Outcomes at Postchemotherapy RPLNDSean Q Kern, Naveen Krishnan, Nabil Adra, et al.
Journal of Clinical Pathology|June 6, 2019
Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomyMartin J Magers, Hristos Z Kaimakliotis, Marcelo P Barboza, et al.
Clinical Genitourinary Cancer|December 26, 2022
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate CancerNeal Shore, Begoña Mellado, Satish Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2023
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell TumorsJennifer M King, Michael Cheng, Kenneth Kesler, et al.
Clinical Genitourinary Cancer|April 23, 2023
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-onlyNoah H Richardson, Sandra K Althouse, Ryan Ashkar, et al.
The Journal of Urology|February 1, 2020
Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant ChemotherapyAntoin Douglawi, Adam Calaway, Isamu Tachibana, et al.
Investigational New Drugs|June 27, 2022
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumorsNabil Adra, David J Vaughn, Lawrence H Einhorn, et al.
Urologic Oncology|April 17, 2022
Artificial intelligence in prostate cancer: Definitions, current research, and future directionsRose S George, Arkar Htoo, Michael Cheng, et al.
Cancer Medicine|February 6, 2025
Prediction Model for Brain Metastasis in Patients With Metastatic Germ-Cell TumorsTareq Salous, Ryan Ashkar, Sandra K Althouse, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2026
How to Optimize Treatment for Patients With Poor-Risk Testicular CancerNoah Richardson, Alok K Tewari, Patrizia Giannatempo, et al.
Pageof 10